Viridian Therapeutics COO Carrie Melvin departs effective April 11, 2023

Viridian Therapeutics, Inc.\DE

Carrie Melvin ceased as COO effective April 11, 2023; severance benefits provided per employment agreement.
Severance treated as involuntary not-for-cause termination, subject to release and restrictive covenants.
No replacement named in the filing; succession plans not disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carrie Melvin

Chief Operating Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-04-11
Filed: April 12, 2023, 7:59 PM ET

On April 12, 2023, Viridian Therapeutics, Inc. (the “Company”) announced that Carrie Melvin has ceased to serve as the Company’s Chief Operating Officer, effective April 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carrie Melvin departed as Chief Operating Officer at Viridian Therapeutics, Inc.\DE.

Action: ceased to serve
Role: Chief Operating Officer

Exact text from the filing

On April 12, 2023, Viridian Therapeutics, Inc. (the “Company”) announced that Carrie Melvin has ceased to serve as the Company’s Chief Operating Officer, effective April 11, 2023.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-098482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.